Industry
Featured experience
Novo Nordisk acquisition of certain Catalent sites from Novo Holdings
We are advising Novo Nordisk on the acquisition
AbbVie $15 billion senior notes offering
The investment-grade offering comprised seven tranches
Auna $360 million U.S. IPO
We advised Auna on its U.S. IPO and NYSE listing
Trial victory in patent infringement case for Magnolia Medical Technologies
We served as lead trial counsel for Magnolia Medical in an action against its sole competitor
Labcorp $2 billion senior notes offering
The investment-grade notes are due 2030, 2032 and 2034
Novartis $3.7 billion notes offering
We advised Novartis on the investment-grade debt offering
MBX Biosciences $188 million IPO
The shares are listed on the Nasdaq Global Select Market
Terns Pharmaceuticals $173 million stock and pre-funded warrants offering
The shares are listed on the Nasdaq Global Select Market
Ionis Pharmaceuticals $500.3 million follow-on offering
The shares are listed on the Nasdaq Global Select Market
Illumina $500 million notes offering
The 4.65% investment-grade notes are due 2026
Jazz Pharmaceuticals $1 billion exchangeable senior notes offering
The exchangeable notes are due 2030
McKesson $2.49 billion acquisition of controlling interest in Core Ventures
We are advising McKesson on the transaction
Owens & Minor $1.4 billion Rotech acquisition financing
We are advising the lead arrangers on the financing
Eli Lilly $5 billion notes offering
The investment-grade notes are due 2027, 2029, 2034, 2054 and 2064